Revolution Medicines (NASDAQ: RVMD) received an upgrade to ‘hold’ rating from ‘sell’ by Zacks Research on Saturday. Zacks has stated that Revolution Medicines is an oncological company in the clinical stage. They emphasize the growing targeted therapies in order to inhibit the abstract frontier objectives of the dangerous cancer conduits. The firm is based in the US.
On Friday, the company started at $45.50. Their lowest in 1 year is $17.34 while the highest is $56.18. Their 50 day rolling average is $45.48 while the 200 day rolling average is $38.66.
According to their 1st March reports, their quarterly EPS earnings was $0.52 that missed the $0.38 consensus estimate by almost $0.14. They had a 191.17% net negative margin with a 32.25% negative equity return. Research analysts expect the company to release an EPS of -1.81 for the ongoing year.
RVMD Stock Market Ventures
SVB Leerink upgraded the price objective of Revolution Medicine shares to $55 from $46 and gave a rating of ‘outperform’. JPMorgan Chase and Co. raised it to $44 from $33. 2 equities analysts allotted a rating of ‘hold’ and 4 assigned ‘buy’ recommendations. The firm has an average ‘buy’ recommendation with a $48.20 average price objective.
Mark Goldsmith, an insider, sold off 5,000 RVMD shares at $45.42 EPS worth $227,000. Barbara Weber, the Director, sold off 5,336 RVMD shares at $45 worth $240,120. 30,336 RVMD shares have been sold by insiders in the previous quarter worth $1,543,970.
McCarthy Management purchased new holdings in Revolution Medicines stock, owning $51,000 worth shares. Penserra Management acquired a new stake and own $60,000 worth of shares. Pacer Advisors purchased a new position, owning $90,000 worth of shares. Retirement System of Arizona State acquired a new stake and owns $227,000 worth of shares. The Amalgamated bank purchased a new position, owning $209,000 worth of shares. 85.81% RVMD stock is owned by institutional investors.
